Aldehyde oxidase mediated drug metabolism: an underpredicted obstacle in drug discovery and development

References

• Akabane T, Gerst N, Masters JN, Tamura KJX. 2012. A quantitative approach to hepatic clearance prediction of metabolism by aldehyde oxidase using custom pooled hepatocytes. Xenobiotica 42(9):863–871.
   PubMed Web of Science ®Google Scholar
• Akabane T, Tanaka K, Irie M, Terashita S, Teramura T. 2011. Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica 41(5):372–384.
   PubMed Web of Science ®Google Scholar
• Alfaro JF, Joswig-Jones CA, Ouyang W, Nichols J, Crouch GJ, Jones J. 2009. Purification and mechanism of human aldehyde oxidase expressed in Escherichia coli. Drug Metab Dispos. 37(12):2393–2398.
   PubMed Web of Science ®Google Scholar
• Amano T, Fukami T, Ogiso T, Hirose D, Jones JP, Taniguchi T, Nakajima M. 2018. Identification of enzymes responsible for dantrolene metabolism in the human liver: a clue to uncover the cause of liver injury. Biochem Pharmacol. 151:69–78.
   PubMed Web of Science ®Google Scholar
• Argikar UA, Potter PM, Hutzler JM, Marathe PH. 2016. Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-glucuronosyltransferase: focus on reaction phenotyping and prediction of human clearance. AAPS J. 18(6):1391–1405.
   PubMed Web of Science ®Google Scholar
• Baranczewski P, Stańczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P, Postlind H. 2006. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep. 58(4):453–472.
   PubMed Web of Science ®Google Scholar
• Barr JT, Jones JP. 2011. Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions. Drug Metab Dispos. 39(12):2381–2386.
   PubMed Web of Science ®Google Scholar
• Barr JT, Jones JP. 2013. Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase. Drug Metab Dispos. 41(1):24–29.
   PubMed Web of Science ®Google Scholar
• Barr JT, Jones JP, Joswig-Jones CA, Rock DA. 2013. Absolute quantification of aldehyde oxidase protein in human liver using liquid chromatography–tandem mass spectrometry. Mol Pharmaceutics. 10(10):3842–3849.
   PubMed Web of Science ®Google Scholar
• Başaran R, Benay C. 2017. Flavin containing monooxygenases and metabolism of xenobiotics. Turk J Pharm Sci. 14(1):90–94.
   PubMed Web of Science ®Google Scholar
• Beedham C, Bruce S, Rance D. 1987. Tissue distribution of the molybdenum hydroxylases, aldehyde. Eur J Drug Metab Pharmacokinet. 12(4):303–306.
   PubMed Web of Science ®Google Scholar
• Behera D, Pattem R, Gudi G. 2014. Effect of commonly used organic solvents on aldehyde oxidase-mediated vanillin, phthalazine and methotrexate oxidation in human, rat and mouse liver subcellular fractions. Xenobiotica 44(8):722–733.
   PubMed Web of Science ®Google Scholar
• Belete TM. 2022. Recent updates on the development of deuterium-containing drugs for the treatment of cancer. Drug Des Devel Ther. 16:3465–3472.
   PubMed Web of Science ®Google Scholar
• Business Wire. 2022. US Food and Drug Administration approves Sotyktu™ (deucravacitinib) oral treatment for adults with moderate-to-severe plaque psoriasis. CA, USA: Business Wire.
   Google Scholar
• Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW, et al. 2013. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04979064 through structure-based drug design. ACS Med Chem Lett. 4(1):91–97.
   PubMed Web of Science ®Google Scholar
• Cheshmazar N, Dastmalchi S, Terao M, Garattini E, Hamzeh-Mivehroud M. 2019. Aldehyde oxidase at the crossroad of metabolism and preclinical screening. Drug Metab Rev. 51(4):428–452.
   PubMed Web of Science ®Google Scholar
• Coelho C, Foti A, Hartmann T, Santos-Silva T, Leimkühler S, Romão MJ. 2015. Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase. Nat Chem Biol. 11(10):779–783.
   PubMed Web of Science ®Google Scholar
• Coelho C, Mahro M, Trincao J, Carvalho AT, Ramos MJ, Terao M, Garattini E, Leimkuhler S, Romao MJ. 2012. The first mammalian aldehyde oxidase crystal structure: insights into substrate specificity. J Biol Chem. 287(48):40690–40702.
   PubMed Web of Science ®Google Scholar
• Crouch RD, Hutzler JM, Daniels JS. 2018. A novel in vitro allometric scaling methodology for aldehyde oxidase substrates to enable selection of appropriate species for traditional allometry. Xenobiotica 48(3):219–231.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Sun H, Xiang C, Hu Q, Jiang Y, Kang P. 2012. Effect of structural variation on aldehyde oxidase-catalyzed oxidation of zoniporide. Drug Metab Dispos. 40(8):1575–1587.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Xiang C, Kang P, Zhou S. 2013. Interspecies variation in the metabolism of zoniporide by aldehyde oxidase. Xenobiotica 43(5):399–408.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Zhang C, Chen W, Smolarek T, Obach RS, Loi C-M. 2010. Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences. Drug Metab Dispos. 38(4):641–654.
   PubMed Web of Science ®Google Scholar
• De Sousa Mendes M, L Orton A, Humphries HE, Jones B, Gardner I, Neuhoff S, Pilla Reddy V. 2020. A laboratory-specific scaling factor to predict the in vivo human clearance of aldehyde oxidase substrates. Drug Metab Dispos. 48(11):1231–1238.
   PubMed Web of Science ®Google Scholar
• Di L. 2014. The role of drug metabolizing enzymes in clearance. Expert Opin Drug Metab Toxicol. 10(3):379–393.
   PubMed Web of Science ®Google Scholar
• Diamond S, Boer J, Maduskuie TP, Falahatpisheh N, Li Y, Yeleswaram S. 2010. Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos. 38(8):1277–1285.
   PubMed Web of Science ®Google Scholar
• Dittrich C, Greim G, Borner M, Weigang-Köhler K, Huisman H, Amelsberg A, Ehret A, Wanders J, Hanauske A, Fumoleau P. 2002. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 38(8):1072–1080.
   PubMed Web of Science ®Google Scholar
• Firestine SM, Davisson VJ. 1993. A tight binding inhibitor of 5-aminoimidazole ribonucleotide carboxylase. J Med Chem. 36(22):3484–3486.
   PubMed Web of Science ®Google Scholar
• Foti A, Hartmann T, Coelho C, Santos-Silva T, Romão MJ, Leimkühler S. 2016. Optimization of the expression of human aldehyde oxidase for investigations of single-nucleotide polymorphisms. Drug Metab Dispos. 44(8):1277–1285.
   PubMed Web of Science ®Google Scholar
• Fu C, Di L, Han X, Soderstrom C, Snyder M, Troutman MD, Obach RS, Zhang H. 2013. Aldehyde oxidase 1 (AOX1) in human liver cytosols: quantitative characterization of AOX1 expression level and activity relationship. Drug Metab Dispos. 41(10):1797–1804.
   PubMed Web of Science ®Google Scholar
• Gajula SNR, Nadimpalli N, Sonti R. 2021. Drug metabolic stability in early drug discovery to develop potential lead compounds. Drug Metab Rev. 53(3):459–477.
   PubMed Web of Science ®Google Scholar
• Galloway SM. 2017. International regulatory requirements for genotoxicity testing for pharmaceuticals used in human medicine, and their impurities and metabolites. Environ Mol Mutagen. 58(5):296–324.
   PubMed Web of Science ®Google Scholar
• Garattini E, Fratelli M, Terao M. 2009. The mammalian aldehyde oxidase gene family. Hum Genomics. 4(2):119–130.
   PubMedGoogle Scholar
• Garattini E, Terao M. 2011. Increasing recognition of the importance of aldehyde oxidase in drug development and discovery. Drug Metab Rev. 43(3):374–386.
   PubMed Web of Science ®Google Scholar
• Garattini E, Terao M. 2012. The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol. 8(4):487–503.
   PubMed Web of Science ®Google Scholar
• Glatthar R, Stojanovic A, Troxler T, Mattes H, Möbitz H, Beerli R, Blanz J, Gassmann E, Drückes P, Fendrich G, et al. 2016. Discovery of imidazoquinolines as a novel class of potent, selective, and in vivo efficacious cancer Osaka thyroid (COT) kinase inhibitors. J Med Chem. 59(16):7544–7560.
   PubMed Web of Science ®Google Scholar
• Hartmann T, Terao M, Garattini E, Teutloff C, Alfaro JF, Jones JP, Leimkühler S. 2012. The impact of single nucleotide polymorphisms on human aldehyde oxidase. Drug Metab Dispos. 40(5):856–864.
   PubMed Web of Science ®Google Scholar
• Hayes A, Mok NY, Liu M, Thai C, Henley AT, Atrash B, Lanigan RM, Sejberg J, Le Bihan Y-V, Bavetsias V, et al. 2017. Pyrido[3,4-d]pyrimidin-4(3H)-one metabolism mediated by aldehyde oxidase is blocked by C2-substitution. Xenobiotica 47(9):771–777.
   PubMed Web of Science ®Google Scholar
• Helmer E, Nicolas JM, Long J, Roffel AF, Jones E, Chanteux H, Diaz N, Garratt H, Bosje T. 2017. A dual-administration microtracer technique to characterize the absorption, distribution, metabolism, and excretion of [(14) C]Seletalisib (UCB5857) in healthy subjects. J Clin Pharmacol. 57(12):1582–1590.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Cerny MA, Yang Y-S, Asher C, Wong D, Frederick K, Gilpin K. 2014. Cynomolgus monkey as a surrogate for human aldehyde oxidase metabolism of the EGFR inhibitor BIBX1382. Drug Metab Dispos. 42(10):1751–1760.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Obach RS, Dalvie D, Zientek MA. 2013. Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. Expert Opin Drug Metab Toxicol. 9(2):153–168.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Yang YS, Albaugh D, Fullenwider CL, Schmenk J, Fisher MB. 2012. Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos. 40(2):267–275.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Yang YS, Brown C, Heyward S, Moeller T. 2014. Aldehyde oxidase activity in donor-matched fresh and cryopreserved human hepatocytes and assessment of variability in 75 donors. Drug Metab Dispos. 42(6):1090–1097.
   PubMed Web of Science ®Google Scholar
• Jensen KG, Jacobsen AM, Bundgaard C, Nilausen DO, Thale Z, Chandrasena G, Jorgensen M. 2017. Lack of exposure in a first-in-man study due to aldehyde oxidase metabolism: investigated by use of 14C-microdose, humanized mice, monkey pharmacokinetics, and in vitro methods. Drug Metab Dispos. 45(1):68–75.
   PubMed Web of Science ®Google Scholar
• Jia H, Dai G, Weng J, Zhang Z, Wang Q, Zhou F, Jiao L, Cui Y, Ren Y, Fan S, et al. 2014. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2, 3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem. 57(18):7577–7589.
   PubMed Web of Science ®Google Scholar
• Johns DG. 1967. Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. J Clin Invest. 46(9):1492–1505.
   PubMed Web of Science ®Google Scholar
• Katsnelson A. 2013. Heavy drugs draw heavy interest from pharma backers. Nat Med. 19(6):656–656.
   PubMed Web of Science ®Google Scholar
• Kaye B, Offerman JL, Reid JL, Elliott HL, Hillis WS. 1984. A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica. 14(12):935–945.
   PubMed Web of Science ®Google Scholar
• Kitamura S, Sugihara K, Nakatani K, Ohta S, Ohhara T, Ninomiya S, Green CE, Tyson CA. 1999. Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. IUBMB Life. 48(6):607–611.
   PubMed Web of Science ®Google Scholar
• Kozminski KD, Selimkhanov J, Heyward S, Zientek MA. 2021. Contribution of extrahepatic aldehyde oxidase activity to human clearance. Drug Metab Dispos. 49(9):743–749.
   PubMed Web of Science ®Google Scholar
• Kücükgöze G, Leimkühler S. 2018. Direct comparison of the four aldehyde oxidase enzymes present in mouse gives insight into their substrate specificities. PLOS One. 13(1):e0191819.
   PubMed Web of Science ®Google Scholar
• Kurosaki M, Bolis M, Fratelli M, Barzago MM, Pattini L, Perretta G, Terao M, Garattini E. 2013. Structure and evolution of vertebrate aldehyde oxidases: from gene duplication to gene suppression. Cell Mol Life Sci. 70(10):1807–1830.
   PubMed Web of Science ®Google Scholar
• Lepri S, Ceccarelli M, Milani N, Tortorella S, Cucco A, Valeri A, Goracci L, Brink A, Cruciani G. 2017. Structure-metabolism relationships in human-AOX: chemical insights from a large database of aza-aromatic and amide compounds. PNAS. 114(16):3178–3187.
   PubMed Web of Science ®Google Scholar
• Li Y, Xu J, Lai WG, Whitcher-Johnstone A, Tweedie DJ. 2012. Metabolic switching of BILR 355 in the presence of Ritonavir. II. Uncovering novel contributions by gut bacteria and aldehyde oxidase. Drug Metab Dispos. 40(6):1130–1137.
   PubMed Web of Science ®Google Scholar
• Linton A, Kang P, Ornelas M, Kephart S, Hu Q, Pairish M, Jiang Y, Guo C. 2011. Systematic structure modifications of imidazo[1,2-a]pyrimidine to reduce metabolism mediated by aldehyde oxidase (AO). J Med Chem. 54(21):7705–7712.
   PubMed Web of Science ®Google Scholar
• Lolkema MP, Bohets HH, Arkenau H-T, Lampo A, Barale E, de Jonge MJ, van Doorn L, Hellemans P, de Bono JS, Eskens FA. 2015. The c-Met tyrosine kinase inhibitor JNJ-38877605 causes renal toxicity through species-specific insoluble metabolite formation. Clin Cancer Res. 21(10):2297–2304.
   PubMed Web of Science ®Google Scholar
• Lynch T, Price A. 2007. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 76(3):391–396.
   PubMed Web of Science ®Google Scholar
• Lyon. 2017. The effects of organ preservation solution on aldehyde oxidase and xanthine oxidase activity in pooled human liver S9. Poster session presented at: 9th International ISSX Meeting; September 2010; Istanbul, Turkey, Poster 247.
   Google Scholar
• Manevski N, King L, Pitt WR, Lecomte F, Toselli F. 2019. Metabolism by aldehyde oxidase: drug design and complementary approaches to challenges in drug discovery. J Med Chem. 62(24):10955–10994.
   PubMed Web of Science ®Google Scholar
• Meanwell NA. 2011. Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem. 54(8):2529–2591.
   PubMed Web of Science ®Google Scholar
• Metz S, Thiel W. 2009. A combined QM/MM study on the reductive half-reaction of xanthine oxidase: substrate orientation and mechanism. J Am Chem Soc. 131(41):14885–14902.
   PubMed Web of Science ®Google Scholar
• Nagarathnam D, Miao SW, Lagu B, Chiu G, Fang J, Murali Dhar TG, Zhang J, Tyagarajan S, Marzabadi MR, Zhang F, et al. 1999. Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 1. Structure-activity relationship in dihydropyrimidinones. J Med Chem. 42(23):4764–4777.
   PubMed Web of Science ®Google Scholar
• Obach RS. 2004. Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos. 32(1):89–97.
   PubMed Web of Science ®Google Scholar
• Ogiso T, Fukami T, Mishiro K, Konishi K, Jones JP, Nakajima M. 2018. Substrate selectivity of human aldehyde oxidase 1 in reduction of nitroaromatic drugs. Arch Biochem Biophys. 659:85–92.
   PubMed Web of Science ®Google Scholar
• Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, Tran TD. 2010. Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem. 53(24):8441–8460.
   PubMed Web of Science ®Google Scholar
• Pryde DC, Tran T-D, Jones P, Duckworth J, Howard M, Gardner I, Hyland R, Webster R, Wenham T, Bagal S, et al. 2012. Medicinal chemistry approaches to avoid aldehyde oxidase metabolism. Bioorg Med Chem Lett. 22(8):2856–2860.
   PubMed Web of Science ®Google Scholar
• Rao Gajula SN, Pillai MS, Samanthula G, Sonti R. 2021. Cytochrome P450 enzymes: a review on drug metabolizing enzyme inhibition studies in drug discovery and development. Bioanalysis 13(17):1355–1378.
   Web of Science ®Google Scholar
• Rao Gajula SN, Reddy GN, Reddy DS, Sonti R. 2020. Pharmacokinetic drug–drug interactions: an insight into recent US FDA-approved drugs for prostate cancer. Bioanalysis 12(22):1647–1664.
   PubMed Web of Science ®Google Scholar
• Renard JF, Arslan D, Garbacki N, Pirotte B, de Leval X. 2009. Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors. J Med Chem. 52(19):5864–5871.
   PubMed Web of Science ®Google Scholar
• Sahi J, Khan KK, Black CB. 2008. Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fraction from mouse, rat, monkey and human. Drug Metab Lett. 2(3):176–183.
   PubMedGoogle Scholar
• Sanoh S, Horiguchi A, Sugihara K, Kotake Y, Tayama Y, Ohshita H, Tateno C, Horie T, Kitamura S, Ohta S. 2012. Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. Drug Metab Dispos. 40(2):322–328.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Nozaki K, Murai H, Terashita S, Teramura T, Ohta S. 2012. Prediction of human metabolism of FK3453 by aldehyde oxidase using chimeric mice transplanted with human or rat hepatocytes. Drug Metab Dispos. 40(1):76–82.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Ohta S. 2014. Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics. Biopharm Drug Dispos. 35(2):71–86.
   PubMed Web of Science ®Google Scholar
• Sodhi JK, Wong S, Kirkpatrick DS, Liu L, Khojasteh SC, Hop CECA, Barr JT, Jones JP, Halladay JS. 2015. A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834. Drug Metab Dispos. 43(6):908–915.
   PubMed Web of Science ®Google Scholar
• Strelevitz TJ, Orozco CC, Obach RS. 2012. Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. Drug Metab Dispos. 40(7):1441–1448.
   PubMed Web of Science ®Google Scholar
• Sugihara K, Kitamura S, Tatsumi K. 1995. Strain differences of liver aldehyde oxidase activity in rats. Biochem Mol Biol Int. 37(5):861–869.
   PubMedGoogle Scholar
• Terao M, Garattini E, Romão MJ, Leimkühler S. 2020. Evolution, expression, and substrate specificities of aldehyde oxidase enzymes in eukaryotes. J Biol Chem. 295(16):5377–5389.
   PubMed Web of Science ®Google Scholar
• Testa B, Mayer JM. 2006. Hydrolysis in drug and prodrug metabolism. Weinheim, Germany: Verlag Helvetica Chimica Acta; p. 81–162.
   Google Scholar
• Tran TD, Pryde DC, Jones P, Adam FM, Benson N, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, et al. 2011. Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection. Bioorg Med Chem Lett. 21(8):2389–2393.
   PubMed Web of Science ®Google Scholar
• Tucker GT, Houston JB, Huang SM. 2001. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential–towards a consensus. Br J Clin Pharmacol. 52(1):107–117.
   PubMed Web of Science ®Google Scholar
• Tung R. 2010. The development of deuterium-containing drugs. Innov Pharm Technol. 32:24–28.
   Google Scholar
• Vardavas AI, Ozcagli E, Fragkiadaki P, Stivaktakis PD, Tzatzarakis MN, Alegakis AK, Vasilaki F, Kaloudis K, Tsiaoussis J, Kouretas D, et al. 2018. The metabolism of imidacloprid by aldehyde oxidase contributes to its clastogenic effect in New Zealand rabbits. Mutat Res Genet Toxicol Environ Mutagen. 829–830:26–32.
   PubMed Web of Science ®Google Scholar
• Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, Jhoti H. 2004. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305(5684):683–686.
   PubMed Web of Science ®Google Scholar
• Yang X, Johnson N, Di L. 2019. Evaluation of cytochrome P450 selectivity for hydralazine as an aldehyde oxidase inhibitor for reaction phenotyping. J Pharm Sci. 108(4):1627–1630.
   PubMed Web of Science ®Google Scholar
• Young RJ, Leeson PD. 2018. Mapping the efficiency and physicochemical trajectories of successful optimizations. J Med Chem. 61(15):6421–6467.
   PubMed Web of Science ®Google Scholar
• Young WB, Barbosa J, Blomgren P, Bremer MC, Crawford JJ, Dambach D, Eigenbrot C, Gallion S, Johnson AR, Kropf JE, et al. 2016. Discovery of highly potent and selective Bruton’s tyrosine kinase inhibitors: pyridazinone analogs with improved metabolic stability. Bioorg Med Chem Lett. 26(2):575–579.
   PubMed Web of Science ®Google Scholar
• Zetterberg C, Maltais F, Laitinen L, Liao S, Tsao H, Chakilam A, Hariparsad N. 2016. VX-509 (decernotinib)-mediated CYP3A time-dependent inhibition: an aldehyde oxidase metabolite as a perpetrator of drug-drug interactions. Drug Metab Dispos. 44(8):1286–1295.
   PubMed Web of Science ®Google Scholar
• Zhan Z, Peng X, Sun Y, Ai J, Duan W. 2018. Evaluation of deuterium-labeled JNJ38877605: pharmacokinetic, metabolic, and in vivo antitumor profiles. Chem Res Toxicol. 31(11):1213–1218.
   PubMed Web of Science ®Google Scholar
• Zhang D. 2014. Evaluation of the allometric exponents in prediction of human drug clearance [Doctor of Philosophy]. Virginia: Virginia Commonwealth University.
   Google Scholar
• Zhang JW, Xiao W, Gao ZT, Yu ZT, Zhang JY. 2018. Metabolism of c-Met kinase inhibitors containing quinoline by aldehyde oxidase, electron donating, and steric hindrance effect. Drug Metab Dispos. 46(12):1847–1855.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu HH, Weller P, Zheng M, Tao W, Wang J, Liao G, Monshouwer M, Peltz G. 2011. In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor. Pharmacogenomics J. 11(1):15–24.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Tang W. 2018. Drug metabolism in drug discovery and development. Acta Pharm Sin B. 8(5):721–732.
   PubMed Web of Science ®Google Scholar
• Zientek M, Jiang Y, Youdim K, Obach RS. 2010. In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos. 38(8):1322–1327.
   PubMed Web of Science ®Google Scholar